GlycoMimetics Inc (NASDAQ:GLYC) Director Buys $31,800.00 in Stock

GlycoMimetics Inc (NASDAQ:GLYC) Director Daniel M. Junius bought 10,000 shares of GlycoMimetics stock in a transaction on Tuesday, August 13th. The shares were purchased at an average cost of $3.18 per share, for a total transaction of $31,800.00. Following the acquisition, the director now owns 18,000 shares in the company, valued at $57,240. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of GlycoMimetics stock traded up $0.35 on Friday, reaching $3.40. 5,307 shares of the company were exchanged, compared to its average volume of 1,926,945. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.54 and a current ratio of 17.54. The company’s 50-day moving average is $9.28 and its two-hundred day moving average is $11.27. The firm has a market cap of $137.35 million, a price-to-earnings ratio of -2.84 and a beta of 2.45. GlycoMimetics Inc has a 1-year low of $2.64 and a 1-year high of $16.35.

GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). As a group, sell-side analysts forecast that GlycoMimetics Inc will post -1.49 earnings per share for the current year.



A number of research firms have commented on GLYC. SunTrust Banks downgraded GlycoMimetics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $23.00 to $5.00 in a report on Monday, August 5th. BidaskClub downgraded GlycoMimetics from a “hold” rating to a “sell” rating in a report on Wednesday, July 24th. Zacks Investment Research raised GlycoMimetics from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a report on Wednesday, August 7th. HC Wainwright reduced their target price on GlycoMimetics from $23.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, August 5th. Finally, Jefferies Financial Group downgraded GlycoMimetics from a “buy” rating to a “hold” rating in a report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. GlycoMimetics presently has an average rating of “Hold” and an average target price of $13.45.

Several institutional investors have recently made changes to their positions in the company. Candriam Luxembourg S.C.A. acquired a new stake in GlycoMimetics in the 1st quarter valued at approximately $915,000. Millennium Management LLC bought a new position in GlycoMimetics during the 4th quarter valued at $222,000. Dimensional Fund Advisors LP boosted its stake in GlycoMimetics by 58.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 617,420 shares of the biotechnology company’s stock valued at $5,847,000 after purchasing an additional 228,664 shares in the last quarter. Two Sigma Investments LP bought a new position in GlycoMimetics during the 4th quarter valued at $152,000. Finally, Geode Capital Management LLC boosted its stake in GlycoMimetics by 16.2% during the 4th quarter. Geode Capital Management LLC now owns 412,003 shares of the biotechnology company’s stock valued at $3,901,000 after purchasing an additional 57,392 shares in the last quarter.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

Read More: What is Cost of Capital?

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.